Pneumonia Testing Market to Reach $1,738 Million by 2023

According to a new report published by Allied Market Research, titled, Pneumonia Testing Market by Method, Technology, Type, End User, and Geography: Global Opportunity Analysis and Industry Forecast, 2017-2023, the pneumonia testing market accounted for $932 million in 2016, and is estimated to reach $1,738 million by 2023, registering a CAGR of 9.2% from 2017 to 2023.. North America is the highest contributor in the pneumonia testing market in 2016; however, Asia-Pacific is expected to witness the highest growth rate during the forecast period.

Click Here To Access Free Sample Report: https://www.alliedmarketresearch.com/request-sample/3776

Pneumonia is a type of lung infection caused by bacteria, such as Streptococcus pneumonia, virus, fungi, and parasites. In pneumonia, the air sacs of lungs called as alveoli are filled with fluid or pus that causes inflammation. The symptoms of pneumonia include short breathing, fever, chest pain, nausea, and vomiting; however, these clinical symptoms overlap with many other diseases such as asthma, bronchitis, and common cold, making it difficult to diagnose pneumonia. Physicians recommend tests such as blood tests, sputum test, pleural fluid culture, and pulse oximetry test to confirm the onset of pneumonia. As per the data by WHO, pneumonia is one of the major factors causing death in children, accounting for almost 1.2 million children under the age of five die annually. This disease is most prevalent in South Asia and African countries.

Recent advancement in pneumonia testing systems such as the development of enhanced nucleic acid detection tests and advancement in POC tests is the major factor that contributes toward the growth of the pneumonia testing market. Moreover, increase in awareness toward early diagnosis and rise in government expenditures on healthcare fuel the market growth. However, limited detection capability & accuracy of some of the pneumonia testing products and regulatory & economic hurdles hamper the market growth. Conversely, surge in adoption of molecular diagnostic testing and high untapped market potential in the developing economies are anticipated to provide lucrative opportunities for the market.

The global pneumonia testing market is segmented on the basis of market, by method, type, technology, end user, and region. In terms of method, the market is classified into immunodiagnostics, molecular diagnostics, and point-of-care (POC) testing. By type, it is bifurcated into analyzers and consumables. Based on technology, it is categorized into enzyme linked immunosorbent assay (ELISA), immunofluorescence, western blot, polymerase chain reaction (PCR), immunohistochemistry (IHC), and others. Depending on end user, it is divided into hospitals, diagnostic laboratories, homecare, and others. Based on region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The POC testing segment was the major contributor to the market in 2016, due to multiple benefits offered by this technique such as technological advancements, ease of use, and rapid results. The consumables segment is estimated to register the highest growth rate during the forecast period, owing to the smaller shelf-life of consumables and their frequent usage for pneumonia tests 2017-2023.

Among the end users, diagnostic laboratories occupied the major share of the pneumonia testing market in 2016, due to large number of tests performed for diagnosis of pneumonia.

In 2016, North America accounted for maximum contribution to the total revenue generated, owing to rise in prevalence of pneumonia and technological advancements in various pneumonia testing products. However, Asia is projected to grow at the highest CAGR during the forecast period, owing to increase in investments by major companies in R&D activities.

For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/3776

Key Findings of the Pneumonia Testing Market:
o POC testing is projected to grow at the highest rate during the analysis period.
o Diagnostic laboratories segment generated the highest revenue, and is expected to continue its dominance in future.
o North America dominated global pneumonia testing market in 2016, and is projected to continue its dominance in future.
o China is expected to grow highest in the Asia-Pacific region during the forecast period.
o ELISA was the largest contributor among the technologies segments.

The key companies profiled in the report include Thermo Fisher Scientific Inc., Abbott Laboratories, F-Hoffmann la Roche Ltd., Hologic Inc., bioMerieux, Becton, Dickenson and Company, Bio-Rad Laboratories Inc., Meridian Biosciences, Quest Diagnostics, and Quidel.

Other prominent players in the value chain include AdvanDx, Beckman Coulter, Cepheid, Concile, Diamedix, DiaSorin, Fast-track Diagnostics, SeraCare, and Trinity Biotech.

Contact:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web:https://www.alliedmarketresearch.com
Follow Us on LinkedIn:https://www.linkedin.com/company/allied-market-research

About Us
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains.

This release was published on openPR.